secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vera Therapeutics, Inc. (VERA)
CIK:        0001831828
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0000950170-24-056283
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vera Therapeutics Q1 net loss $28.4M; cash $403.7M; Phase 3 enrollment on track
-------------------------------------------------------------------------------

- Net loss of $28.4M ($0.56 diluted EPS) vs $30.1M ($0.80) in Q1 2023.
- Cash and equivalents $403.7M after $287.5M financing; runway through approval and launch.
- Positive 72-week Phase 2b ORIGIN data; 96-week topline results expected Q4 2024.
- Pivotal Phase 3 ORIGIN 3 enrollment estimated complete Q3 2024; data 1H 2025.
- Appointed Robert M. Brenner as CMO and William D. Turner as CDO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831828/000095017024056283/0000950170-24-056283-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831828/000095017024056283/vera-20240509.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-056283

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer